Moreover, preclinical and clinical evidence supports the efficacy of BRAF and MEK inhibitor combinations in patients with NSCLC among which the combination of MEK162 and buparlisib (BKM120) significantly inhibits tumor growth in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistant NSCLC cells and overcomes the negative feedback mechanisms in the phosphoinositide 3-kinase (PI3K) pathway [44–46]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.